SUPERNUS PHARMACEUTICALS, INC. Prepaid Expense and Other Assets, Current
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Prepaid Expense and Other Assets, Current of $55.85 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-03
- 2026-06-30: Prepaid Expense and Other Assets, Current $55.85M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $78.09M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $65.33M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $62.08M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $55.85M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $78.09M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $65.33M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $62.08M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $31.42M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $28.93M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $36.09M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $27.40M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $23.17M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $23.77M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $16.68M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $23.93M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $44.77M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $16.30M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $15.78M 10-Q · filed 2023-11-08 | |
| 2022-09-30 | $24.85M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $21.41M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $22.37M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $27.02M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $30.69M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $33.74M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $17.63M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $18.68M 10-K · filed 2022-04-13 | |
| 2020-09-30 | $24.49M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $20.44M 10-Q · filed 2020-08-17 | |
| 2020-03-31 | $12.56M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $11.61M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $18.18M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $21.76M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $20.56M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $8.89M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $9.30M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $14.58M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $6.58M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $6.52M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $5.67M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $4.75M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $4.57M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $2.96M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $4.20M 10-Q · filed 2017-01-20 | |
| 2016-06-30 | $3.27M 10-Q/A · filed 2017-01-23 | |
| 2016-03-31 | $5.00M 10-Q/A · filed 2017-01-20 | |
| 2015-12-31 | $5.26M 10-K · filed 2017-03-16 | $5.29M 10-K · filed 2016-03-09 |
| 2015-09-30 | $6.47M 10-Q/A · filed 2017-01-20 | $6.50M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $4.42M 10-Q/A · filed 2017-01-23 | $4.46M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $3.64M 10-Q/A · filed 2017-01-20 | $3.70M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $3.68M 10-Q/A · filed 2017-01-20 | $3.85M 10-K · filed 2015-03-12 |
| 2014-09-30 | $3.79M 10-Q/A · filed 2017-01-20 | $3.30M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $3.06M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $2.56M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $2.76M 10-K · filed 2015-03-12 | $2.05M 10-K · filed 2014-03-21 |
| 2013-09-30 | $1.81M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $1.91M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $861.00K 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $983.00K 10-K · filed 2014-03-21 | |
| 2012-09-30 | $1.28M 10-Q · filed 2012-11-02 | |
| 2012-06-30 | $1.01M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $618.00K 10-Q · filed 2012-06-08 | |
| 2011-12-31 | $466.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |